Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Free Research Reports on ARNA, DSCO, MNKD and ZIOP Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit


Print article Print article
© Marketwire 2013
2013-02-19 14:29:46 -

NEW YORK, NY -- (Marketwire) -- 02/19/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.



Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) was among the top gainers within the Biotech Industry in 2012. In June 2012, the US Food and Drug Administration approved the company's weight loss drug, BELVIQ, which was the first anti-obesity drug approved by the FDA in over a decade. Shares of Arena have soared over 350 percent year-to-date.





Find out more about Arena Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ARNA : www.bedfordreport.com/ARNA



Discovery Laboratories, Inc. (NASDAQ: DSCO) shares have gained over 25 percent year-to-date. The company's SURFAXIN is the first synthetic, peptide-containing (KL4) surfactant approved by the FDA and the only alternative to animal-derived surfactants. Discovery has recently received a $30 million funding commitment from Deerfield Management.



Find out more about Discovery Laboratories including full access to the free equity report at: www.BedfordReport.com/DSCO : www.bedfordreport.com/DSCO



MannKind Corporation (NASDAQ: MNKD) shares have gained over 7 percent year-to-date. Its lead product candidate, AFREZZA, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.



Find out more about MannKind including full access to the free equity report at: www.BedfordReport.com/MNKD : www.bedfordreport.com/MNKD



ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) shares have gained over 10 percent year-to-date. The company has recently reported that the Phase 3 (PICASSO 3) trial of palifosfamide in first-line metastatic soft tissue sarcoma reached its target number of progression-free survival events.



Find out more about ZIOPHARM Oncology including full access to the free equity report at: www.BedfordReport.com/ZIOP : www.bedfordreport.com/ZIOP



Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.



A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.




Contact Information:

Equity News Circuit
Email Contact : www2.marketwire.com/mw/emailprcntct?id=690C1C66E9D56046



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com